Annovis Bio, Inc. (ANVS)

5.56 -0.53 (-8.70%) 收市：04:00PM EDT

Annovis Bio, Inc.

101 Lindenwood Drive
Suite 225
Malvern, PA 19355
United States
(484) 875-3192
https://www.annovisbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 6

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Maria L. Maccecchini Ph.D.	Founder, CEO, President, Interim Principal Financial Officer & Executive Director	681.2k	無	1951
Dr. Cheng Fang Ph.D.	Senior Vice President of Research & Development	無	無	無
Ms. Eve M. Damiano M.S., RAC	Senior Vice President of Regulatory Operations	無	無	無
Ms. Melissa Gaines	Senior Vice President of Clinical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

公司管治

截至 無 止，Annovis Bio, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。